Clinical data on the selective cyclooxygenase-2-inhibitor celecoxib;Klinische studien zum selektiven cyclooxygenase-2-inhibitor celecoxib

Aktuelle Rheumatologie

Volumn 26, Issue 2, 2001, Pages 75-81

  Fisch, U W ^a   Mahr, G ^b   Vergin, H ^a  

^a Pharmacia GmbH   (Germany)

^b mcp   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; PLACEBO;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPATHOLOGY; LIVER TOXICITY; NEPHROTOXICITY; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STOMACH OBSTRUCTION;

EID: 0035036893     PISSN: 0341051X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-14217     Document Type: Article

References (35)

1. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999; 74: 1095-1105
2. Bensen WG, Agrawal NM, Zhao SZ, Burke TA, Zabinski RA, Maurath CJ, Geis GS. Upper gastrointestinal (UGI) tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. Arthritis Rheum 1999; 42: abstract 430
3. Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS. Upper gastrointestinal tolerability of celecoxib, a cox-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol, 2000; 27: 1876-1883
4. Boyce EG, Breen GA. Celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis. Formulary 1999; 34: 405-417
5. Burke TA, Goldstein JL, Pettitt AD, Maurath CJ, Zhao SZ, Zabinski RA. Increased upper gastrointestinal (UGI) distress among arthritis patients treated with NSAIDs compared to celecoxib and placebo. Value Health 1999; 2: 154-155
6. Burr AM, Yu SS, Zhao WW, Hubbard RC, Geis GS. Serial endoscopies confirm lower incidence of gastroduodenal ulceration with celecoxib as compared to naproxen. Am J Gastroenterol 1999; 94: 2606, abstract 116
7. Caspi A. Celecoxib: A new treatment for the pain of osteoarthritis and rheumatoid arthritis. P & T 1999; 24: 211-212, 217
8. Clemett D, Goa KL. Celecoxib. A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59: 957-980
9. Dougados M, Béhier JM, Jolchine I, Calin A, van der Heijde D, Dolivieri I, Zeidler H, Herman H. Efficacy of celecoxib, a cox-2 specific inhibitor in ankylosing spondylitis: a placebo and conventional NSAID (ketoprofen) six-week control study. Ann Rheum Dis 2000; 59: 204, abstract POS-605
10. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R. Stead H, Verburg KM, Isakson PC, Hubbard RC, Geis GS. Celecoxib versus di-clofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999; 354: 2106-2111
11. Fisch UW, Brauer HG, Mahr G, Vergin H. Cyclooxygenase-2-spezifische Inhibitoren: Grundlegende Aspekte des Wirkmechanismus. Akt Rheumatol 1999; 24: 63-68
12. Fort J. Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J Orthop 1999; 28: 13-18
13. Geba GP, Weaver AL, Schnitzer TJ, Fleischmann RM, Polis AB, Matzura-Wolfe DM, Dixon ME, Gormley GJ. A comparison of rofecoxib to celecoxib and acetaminophen in the treatment of osteoarthritis. Arthritis Rheum 2000; 43 (9, Suppl.): S384
14. Geis GS, Hubbard RC, Woods EM, Lefkowith JB, Yu S, Zhao WW. Efficacy of celecoxib, a COX-2 specific inhibitor, in osteoarthritis of the hip. Arthritis Rheum 1999; 42: abstract 441
15. Geis GS, Hubbard HC, Woods EM, Lefkowith JB, Yu S, Zhao WW. Efficacy and safety of celecoxib, a specific cyclooxygenase-2 (COX-2)inhibitor, in rheumatoid arthritis. Ann Rheum Dis 1999; 99: abstract 854
16. Goldenberg MM. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 1999; 21: 1497-1513
17. Goldstein JL, Agrawal N, Silverstein F, Burr A, Maurath CJ, Verburg KM, et al. Effect of celecoxib (CEL) versus placebo (PBO) or NSAIDs in healing of gastric or duodenal erosions in arthritis patients: analysis of controlled endoscopic studies. AmJ Gastroenterol 1999; 94: 2608, abstract 126
18. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-1690
19. Isakson P, Zweifel B, Masferrer J, Koboldt C, Seibert K, Hubbard R, Geis S, Needleman P. Specific COX-2 inhibitors: from bench to bedside. In: Vane J, Botting J, editors. Selective COX-2 inhibitors. Pharmacology, clinical effects and therapeutic potential. Proceedings of a conference held on March 20-21, 1997 in Cannes, France. Dordrecht: Kluwer Academic Publishers and London: William Harvey Press, 1998: 127-133
20. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib. a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 2000; 40: 124-132
21. McKenna F. Summary of Faculty Presentations - Satellite Symposium at the XV European League Against Rheumatism (EULAR) Congress, Nice, 22 June 2000
22. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999; 21: 2065-2079
23. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibitors in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76-84
24. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Mackich R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, LefkowithJB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-1255
25. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis SG. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591-1602
26. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999; 282: 1921-1928
27. SHEP Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)JAMA 1991; 295: 3255-3264
28. Singh G, Ramey DR, Triadafilopoulos G. Experience with selective COX-2 inhibitors: Safety profile in over 780,000 patient years of use. Poster American Congress of Rheumatology, 63rd Annual Scientific Meeting, November 13-17, Boston, USA: 1999
29. Stucki G, Meier D, Stucki S, Michel BA, Tyndall AG, Dick W, Theiler R. Evaluation einer deutschen Version des WOMAC (Western Ontario und McMaster Universities) Arthroseindex. Z Rheumatol 1996; 55: 40-49
30. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cydooxygenase-2 inhibitor. Am J Ther 2000; 7: 159-175
31. Whelton A. Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, Geis GS. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465-1470
32. Whelton A, Fort J, Puma J, Normandin D, Ello A, Verburg K. Cyclooxygenase-2 specific inhibitors and cardiorenal function. A randomized controlled trial of celecoxib and rofecoxib in elderly hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85-95
33. Williams GW, Ettlinger RE, Ruderman EM, Hubbard RC, Lonien ME, Yu SS, Zhao W, Geis GS. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib. J Clin Rheumatol 2000; 6: 65-74
34. Zhao SZ, Dedhiya SD, Verburg K, Fort J, Osterhaus JT. Celecoxib improves health related quality of life (HRQOL) of elderly patients with osteoarthritis (OA). Arthritis Rheum 1999; 42: abstract 1356
35. Zhao SZ, McMillen JI, Markenson JA, Dedhiya SD, Zhao WW, Osterhaus JT, Yu SS. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999; 19: 1269-1278